Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 131-143

  Ozols, Robert F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER STAGING; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LAPAROTOMY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECOND LOOK SURGERY;

EID: 84934442136     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_11     Document Type: Review

References (34)

1. R.C. Young, L.A. Walton, S.S. Ellenberg, H.D. Homesley, G.D. Wilbanks, D.G. Decker, A. Miller, R. Park, and F. Major Jr., Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 322(15), 1021-1027 (1990).
2. I. Vergote, J. De Brabanter, A. Fyles, K. Bertelsen, N. Einhorn, P. Sevelda, M.E. Gore, J. Kaern, H. Verreist, K. Sjovall, D. Timmerman, J. Vandewalle, M. Van Gramberen, and C.G. Trope, Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, Lancet 357(9251), 176-182 (2001).
3. I.B. Vergote, J. Kaern, V.M. Abeler, E.O. Pettersen, L.N. De Vos, and G. Trope, Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse, Am J Obstet Gynecol 169(1), 40-52 (1993).
4. R.C. Young, M.F. Brady, R.K. Nieberg, H.J. Long, A.R. Mayer, S.S. Lentz, J. Hurteau, and D.S. Alberts, Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - a Gynecologic Oncology Group study, J Clin Oncol 21(23), 4350-4355 (2003).
5. G. Bolis, N. Colombo, S. Pecorelli, V. Torri, S. Marsoni, C. Bonazzi, S. Chiari, G. Favalli, G. Mangili, and M. Presti, Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica, Ann Oncol6(9), 887-893 (1995).
6. J. Bell, M.F. Brady, R.C. Young, J. Lage, J.L. Walker, K.Y. Look, G.S.Rose, and N.M. Spirtos, Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study, Gynecol Oncol 102 432-439 (2006).
7. R.C. Young, Early-stage ovarian cancer: to treat or not to treat, J Natl Cancer Inst 95(2), 94- 95 (2003).
8. I. Vergote and F. Amant, Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer, Gynecol Oncol 102(3), 415-417 (2006).
9. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L. Clarke-Pearson, and M. Davidson, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med 334(1), 1-6 (1996).
10. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, E. Simonsen, G. Stuart, S. Kaye, I. Vergote, R. Blom, R. Grimshaw, R.J. Atkinson, K.D. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tumolo, P. Timmers, J.A. Roy, F. Lhoas, B. Lindvall, M. Bacon, A. Birt, J.E. Andersen, B. Zee, J. Paul, B. Baron, and S. Pecorelli, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J Natl Cancer Inst 92(9), 699-708 (2000).
11. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, S.L. Lentz, R.D. Alvarez, P.R. Kucera, and J.M. Small, Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study, J Clin Oncol 18(1), 106-115 (2000).
12. M.A. Bookman, W.P. McGuire III, D. Kilpatrick, E. Keenan, W.M. Hogan, S.W. Johnson, P. O'Dwyer, E. Rowinsky, H.H. Gallion, and R.F. Ozols, Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group, J Clin Oncol 14 1895-1902 (1996).
13. R. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, R.S. Mannel, K. DeGeest, E.M. Hartenbach, and R. Baergen, Phase III trial of cisplatin and paclitaxel compared to carboplatin and paclitaxel in patients with "optimally" resected stage III ovarian cancer: a GOG study, J Clin Oncol 21(17), 3194-3200 (2003).
14. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundquist, M. Bookman, D. Bowtell, M. Brady, A. Casado, A. Cervantes, E. Eisenhauer, M. Friedlaender, K. Fujiwara, S. Grenman, J.P. Guastalla, P. Harper, T. Hogberg, S. Kaye, H. Kitchener, G. Kristensen, R. Mannel, W. Meier, B. Miller, J.P. Neijt, A. Oza, R. Ozols, M. Parmar, S. Pecorelli, J. Pfisterer, A. Poveda, D. Provencher, E. Pujade-Lauraine, M. Randall, J. Rochon, G. Rustin, S. Sagae, F. Stehman, G. Stuart, E. Trimble, P. Vasey, I. Vergote, R. Verheijen, U. Wagner, 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004), Ann Oncol 16(suppl 8), viii7-viii12 (2005).
15. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schroder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, J. Pfisterer, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J Natl Cancer Inst 95(17), 1320-1329 (2003).
16. M.A. Bookman, GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma, Proc Am Soc Clin Oncol 24(18S), abstract 5002 (2006).
17. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, F.J. Montz, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol 20 1248-1259 (2002).
18. D.G. Allen, A.P.M. Heintz, F.W.M.M. Touw, A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary, Eur J Gynaecol Oncol 16 349-356 (1995).
19. M.E.L. van der Burg, M. van Lent, M. Buyse The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N Engl J Med 332 629-634 (1995).
20. P.G. Rose, S. Nerenstone, M.F. Brady Secondary surgical cytoreduction for advanced ovarian carcinoma, N Engl J Med 351 2489-2497 (2004).
21. T. Thigpen, The if and when of surgical debulking for ovarian carcinoma, N Engl J Med 351 2544-2546 (2004).
22. W.J. Hoskins, W.P. McGuire, M.F. Brady The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma, Am J Obstet Gynecol 170 974-980 (1994).
23. D. Luesley, F. Lawton, G. Blackledge Failure of second-look laparotomy to influence survival in epithelial ovarian cancer, Lancet 2(8611), 599-603 (1988).
24. M.O. Nicoletto, S. Tumolo, R. Talamini Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission - a Northeastern Oncology Cooperative Group - Ovarian Cancer Cooperative Group study, J Clin Oncol 15(3), 994-999 (1997).
25. B.E. Greer, B.N. Bundy, R.F. Ozols, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, R. Mannel, K. DeGeest, E.M. Hartenbach, R.N. Baergen, L.J. Copeland, Implications of secondlook laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study, Gynecol Oncol 99 71-79 (2005).
26. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, R.D. Alvarez, C. Jiang, and D. Alberts, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial, J Clin Oncol 21(13), 2460-2465 (2003).
27. M.A. Varia, F.B. Stehman, B.N. Bundy, J.A. Benda, D.L. Clarke-Pearson, R.D. Alvarez, and H.J. Long, J Clin Oncol 21(15), 2849-2855 (2003).
28. P. Benedetti-Panici, S. Greggi, F. Maneschi Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer, Gynecol Oncol 51 150-154 (1993).
29. J.L. Walker, D. Armstrong, H.Q. Huang Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study, Gynecol Oncol 100 27-32 (2006).
30. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, and R.A. Burger, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med 354 34-43 (2006).
31. Clinical advisory: NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer, Available at www.nlm.nih.gov/ databases/alerts/ovarian-ip-chemo. html (2006).
32. R.F. Ozols, Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel, Gynecol Oncol 103 1-6 (2006).
33. L. Martin and R.J. Schilder, Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects, JNCCN 4 955-966 (2006).
34. R.A. Burger, M. Sill, B.J. Monk Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study, J Clin Oncol 23 (Suppl 1), 457s, Abstract 5009.